ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Role of primary chemoradiotherapy in the management of advanced stage vulvar cancer : Experience of a large cancer center.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatment of advanced vulvar cancer is challenging. The aim of the study was to investigate the potential of primary (chemo)radiotherapy ((C)RT) with regard to clinical outcome and associated prognostic parameters.
methodsA total of 39 patients with squamous cell vulvar cancer receiving primary (C)RT were retrospectively identified through hospital databases. Patient and treatment characteristics as well as outcomes were assessed. Survival statistics were calculated using the Kaplan-Meier method. Univariate analysis was performed using the log-rank test and Spearman's correlation to evaluate associations between patient or treatment characteristics and survival outcomes.
resultsMedian age at diagnosis was 74 years (range 38-92 years). Patients had advanced stage disease with 28.2%/38.5% presenting with FIGO stage III/IV, respectively. All patients received external beam radiotherapy (EBRT) with a median dose to the primary tumor of 66 Gy EQD2 (range 49.6 Gy-72.6 Gy) and to lymph nodes of 53.1 Gy EQD2 (range 44.1 Gy-67.1 Gy). 69.2% received concurrent chemotherapy, mostly cisplatin weekly or mitomycin/5-fluorouracil. 10.3%/64.1% showed clinical complete remission (cCR)/partial remission (cPR) at first follow-up; 7.7% had disease progression. After a median follow-up of 25.5 months (range 0.5-132.9 months), 3‑year locoregional progression-free survival (LRPFS) and overall survival (OS) were 60.2% and 69.6%, respectively. Age and concurrent chemotherapy were the main prognostic parameters associated with improved oncological outcome.
conclusionDefinitive (C)RT plays an important role in the management of advanced vulvar cancer with high response rates and satisfactory oncological outcomes. However, there is still room for improvement and future trials are needed to further assess the potential of definitive CRT, especially with regard to possible combinations with immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.